Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

The hypothesis that quiescent CD4+ T lymphocytes carrying proviral DNA provide a reservoir for human immunodeficiency virus-type 1 (HIV-1) in patients on highly active antiretroviral therapy (HAART) was examined. In a study of 22 patients successfully treated with HAART for up to 30 months, replication-competent virus was routinely recovered from resting CD4+ T lymphocytes. The frequency of resting CD4+ T cells harboring latent HIV-1 was low, 0.2 to 16.4 per 10(6) cells, and, in cross-sectional analysis, did not decrease with increasing time on therapy. The recovered viruses generally did not show mutations associated with resistance to the relevant antiretroviral drugs. This reservoir of nonevolving latent virus in resting CD4+ T cells should be considered in deciding whether to terminate treatment in patients who respond to HAART.

[1]  E A Emini,et al.  Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. , 1997, The New England journal of medicine.

[2]  P. Lipsky,et al.  Phenotypic and functional characterization of human T cell clones. , 1988, Journal of immunology.

[3]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[4]  L. McQuay,et al.  Dilution assay statistics , 1994, Journal of clinical microbiology.

[5]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[6]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[7]  N. Shen,et al.  Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays , 1996, Nature Medicine.

[8]  M. Zupancic,et al.  Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. , 1997, Science.

[9]  J. Mellors,et al.  Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor , 1996, Journal of virology.

[10]  M P Dempsey,et al.  Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. , 1991, Science.

[11]  J. van Lunzen,et al.  Asymptomatic HIV infection is characterized by rapid turnover of HIV RNA in plasma and lymph nodes but not of latently infected lymph‐node CD4+ T cells , 1997, AIDS.

[12]  D. Ho,et al.  Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.

[13]  H. Nitschko,et al.  Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. , 1995, AIDS research and human retroviruses.

[14]  R. Gallo,et al.  Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Robert F. Siliciano,et al.  In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency , 1995, Nature Medicine.

[16]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[17]  P. Sharp,et al.  Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation , 1992, Journal of virology.

[18]  D. Ho,et al.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.

[19]  Ashley T. Haase,et al.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS , 1993, Nature.